ISPE members are invited to comment on the following manuscript, Use of Quantitative Bias Analysis to Evaluate Single Arm Trials with Real-World Data External Controls, submitted as part of the funded manuscript program.
At the conclusion of the comments period, feedback will be provided to the authors, who will thereafter prepare an updated paper for ISPE Board review and endorsement. The final paper will be posted to the ISPE website and shared with members.
Click here for Details: Call for Comments - Use of Quantitative Bias Analysis to Evaluate Single Arm Trials with Real-World Data External Controls
The deadline for comments is Tuesday, October 18.
ISPE is pleased to announce the induction of eight new ISPE Fellows this year.
Click here for details: New ISPE Fellows 2022
View ICPE awards video here
ISPE's SoMe committee manages all ISPE social media accounts. Want something shared or have a suggested post? We'd love to hear from you, submit your ideas to the SoMe committee using this form.
ISOP's 21st Annual meeting is scheduled for 20-23 Sept 2022 in Verona, Italy. More details at www.isop2022verona.org.
Deprescribing, the clinically supervised process of tapering or stopping medications with the goal of minimizing inappropriate medication use and improving patient outcomes, has gained significant attention in the last decade. While deprescribing has been mostly used as a solution to address inappropriate medication use and polypharmacy in older adults, there is growing evidence of its utility throughout the lifespan. In addition, finding the appropriate methodological approach in evaluating the impact of deprescribing interventions on health-related outcomes is a topic of interest for clinicians and pharmacoepidemiologists all around the world. Existing Deprescribing Networks (Canadian Deprescribing Network- CaDeN, US Deprescribing Research Network- USDeN, Australian Deprescribing Network- ADeN, or the Network of European Researchers in Deprescribing - NERD) provide valuable resources for clinicians and researchers. Some of these networks provide useful clinical tools, such as evidence-based guidance for implementing deprescribing protocols in clinical practice, while others focus on researchers, offering training opportunities, pilot funding, and tools for conducting research. The evidence to support deprescribing efforts is based on research showing a wide variety of negative health effects of inappropriate medications and polypharmacy, as well as randomized trials testing the efficacy and/or effectiveness of deprescribing interventions on reducing the use of targeted medications. However, clinical studies of medication withdrawal are limited due to challenges in recruitment and retention of participants, as well as limited power to study clinical outcomes and often limited measures of patient-centered outcomes that matter for patients and their caregivers.
Co-sponsored by the US Deprescribing Research Network (USDeN) and Australian Deprescribing Network (ADeN).
Click Here to Register: Is There a Role for Pharmacoepidemiology in Deprescribing Research
Interested in presenting a webinar? Submit a webinar proposal here
